AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Ophthalmology Therapeutics Market 2019-2023 | Evolving Opportunities with ALLERGAN and Novartis AG | Technavio

November 25, 2019 GMT
Global Ophthalmology Therapeutics Market 2019-2023 | Evolving Opportunities with ALLERGAN and Novartis AG | Technavio
Global Ophthalmology Therapeutics Market 2019-2023 | Evolving Opportunities with ALLERGAN and Novartis AG | Technavio

LONDON--(BUSINESS WIRE)--Nov 25, 2019--

Technavio has been monitoring the global ophthalmology therapeutics market and the market is poised to grow by USD 9.6 billion during 2019-2023 at a CAGR of nearly 6% during the forecast period. Request Free Sample Pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005301/en/

Technavio has announced its latest market research report titled global ophthalmology therapeutics market 2019-2023 (Graphic: Business Wire)

Read the 133-page research report with TOC on “Ophthalmology Therapeutics Market Analysis Report by Product (Retinal disorder therapeutics, Glaucoma therapeutics, Dry eye syndrome therapeutics, Eye infections and inflammation therapeutics, and Other therapeutics), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023”.

The market is driven by the increase in prevalence of eye diseases. In addition, the development of novel drug delivery systems is anticipated to further boost the growth of the ophthalmology therapeutics market.

Eye conditions such as age-related macular degeneration can result in visual impairment and irreversible blindness. The prevalence of conditions such as retinal vein occlusion (RVO) vascular disorder, diabetic macular edema, and diabetic retinopathy is increasing with the growth in the aging population and increase in diabetes. The eye condition of glaucoma can lead to eye disease by damaging the optic nerve of a person. Thus, the increase in prevalence of such eye diseases is driving the demand for ophthalmology therapeutics and will boost market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Ophthalmology Therapeutics Market Companies:

ALLERGAN

ALLERGAN is headquartered in Ireland and operates the business under various segments such as US specialized therapeutics, US general medicine, and International. The company offers Restasis, Alphagan, Lumigan, Ozurdex, Ganfort, and Combigan.

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd is headquartered in Switzerland and offers products through the following business units: Pharmaceuticals and Diagnostics. The company offers LUCENTIS (ranibizumab) and Avastin (bevacizumab).

Novartis AG

Novartis AG is headquartered in Switzerland and operates under various business segments, namely Innovative medicines, Sandoz, and Alcon. The company offers Azarga/Azorga, DUOTRAV, Durezol, LUCENTIS, LUXTURNA, PATANOL, SIMBRINZA, PATADAY and PAZEO, and TRAVATAN, TRAVATAN Z, TRAVATAN BAK Free, and IZBA.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is headquartered in the US and offers products through the business segment, Biopharmaceuticals. The company offers EYLEA, which is used to treat retinal disorders.

Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical Co., Ltd. is headquartered in Japan and offers products through the business segment, Ophthalmology. The company offers Lecrolyn, Tarivid, Cravit, TAPROS, COSOPT, and TRUSOPT.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform

Ophthalmology Therapeutics Product Outlook (Revenue, USD Million, 2019 - 2023)

  • Retinal disorder therapeutics
  • Glaucoma therapeutics
  • Dry eye syndrome therapeutics
  • Eye infections and inflammation therapeutics
  • Other therapeutics

Ophthalmology Therapeutics Regional Outlook (Revenue, USD Million, 2019 - 2023)

  • Asia
  • Europe
  • North America
  • ROW

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.Request a free sample report

Related Reports on Health Careare:

Ophthalmology PACS Market – Global Ophthalmology PACS Market by geography (Asia, Europe, North America, and ROW) and type (on-premise PACS and web/cloud-based PACS).

Ophthalmic Perimeters Market – Global Ophthalmic Perimeters Market by end-users (hospitals, ophthalmology clinics, and others), product (static, combination, and kinetic) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191125005301/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email:media@technavio.com

Website:https://www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: DIABETES PHARMACEUTICAL OPTICAL HEALTH

SOURCE: Technavio Research

Copyright Business Wire 2019.

PUB: 11/25/2019 04:30 AM/DISC: 11/25/2019 04:30 AM

http://www.businesswire.com/news/home/20191125005301/en